| Characteristic | Men, no. (%)* n = 283 | Women, no. (%)* n = 295 | Overall, no. (%)* n = 578 |
|---|---|---|---|
| Age at diagnosis of depression, yr, mean ± SD | 71.8 ± 11.9 | 72.0 ± 12.3 | 71.9 ± 12.1 |
| Diagnosed before Parkinson disease | 121 (42.8) | 121 (41.0) | 242 (41.9) |
| Diagnosed after Parkinson disease | 162 (57.2) | 174 (58.9) | 336 (58.1) |
| Duration of depression, yr, mean ± SD | 5.0 ± 3.1 | 4.8 ± 3.2 | 4.9 ± 3.2 |
| Encounters with a primary care provider, mean ± SD | |||
| 1-year period | 8.3 ± 9.1 | 8.6 ± 8.5 | 8.5 ± 8.8 |
| 2-year period | 17.2 ± 16.5 | 17.7 ± 15.6 | 17.5 ± 16.1 |
| No. of medications for depression, mean ± SD | 1.7 ± 1.2 | 1.9 ± 1.2 | 1.8 ± 1.2 |
| 0 | 44 (15.5) | 36 (12.2) | 80 (13.8) |
| 1 | 76 (26.9) | 91 (30.8) | 167 (28.9) |
| 2 | 96 (33.9) | 82 (27.8) | 178 (30.8) |
| ≥ 3 | 67 (23.7) | 86 (29.2) | 153 (26.5) |
| Type of medication for depression | |||
| Selective serotonin reuptake inhibitors | 140 (49.5) | 162 (54.9) | 302 (52.2) |
| Benzodiazepines and related hypnosedatives | 130 (45.9) | 143 (48.5) | 273 (47.2) |
| Atypical antipsychotic agents | 86 (30.4) | 97 (32.9) | 183 (31.7) |
| Serotonin-norepinephrine reuptake inhibitors | 45 (15.9) | 54 (18.3) | 99 (17.1) |
| Serotonin antagonist and reuptake inhibitors | 44 (15.6) | 31 (10.5) | 75 (13.0) |
| Tricyclics and tetracyclics | 21 (7.4) | 36 (12.2) | 57 (9.9) |
| Amitriptyline† | 9 (3.2) | 17 (6.0) | 26 (4.5) |
| Bipolar medications | 24 (8.5) | 30 (10.2) | 54 (9.3) |
| Monoamine oxidase inhibitors | 5 (1.8) | 4 (1.4) | 9 (1.6) |
| No depression medication | 44 (15.5) | 36 (12.2) | (80) 13.8 |
Note: SD = standard deviation.
*Unless otherwise specified.
†Tricyclic recommended in Canadian guidelines on Parkinson disease.12